The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Genomics of lethal prostate cancer at diagnosis and castration resistance
Open accessAbstract
The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, also studying matching, same-patient, diagnostic, and mCRPC biopsies following treatment. We profiled 470 treatment-naive prostate cancer diagnostic biopsies and, for 61 cases, mCRPC biopsies, using targeted and low-pass whole-genome sequencing (n = 52). Descriptive statistics were used to summarize mutation and copy number profile. Prevalence was compared using Fisher's exact test. Survival correlations were studied using log-rank test. TP53 (27%) and PTEN (12%) and DDR gene defects (BRCA2 7%; CDK12 5%; ATM 4%) were commonly detected. TP53, BRCA2, and CDK12 mutations were markedly more common than described in the TCGA cohort. Patients with RB1 loss in the primary tumor had a worse prognosis. Among 61 men with matched hormone-naive and mCRPC biopsies, differences were identified in AR, TP53, RB1, and PI3K/AKT mutational status between same-patient samples. In conclusion, the genomics of diagnostic prostatic biopsies acquired from men who develop mCRPC differ from those of the nonlethal primary prostatic cancers. RB1/TP53/AR aberrations are enriched in later stages, but the prevalence of DDR defects in diagnostic samples is similar to mCRPC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., Collaco-Moraes, Y., Ward, K., Hindley, R. G., Freeman, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32401-1 · Cited by 3,284
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., Briganti, A., Budäus, L., Hellawell, G., Hindley, R. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801993 · Cited by 3,091
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Self-citationDivergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V. S. K., Varambally, S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4045 · Cited by 1,685
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Self-citationGenomic correlates of clinical outcome in advanced prostate cancer
Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902651116 · Cited by 1,372
Self-citationMutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Ku, S. Y., Rosario, S., Wang, Y., Mu, P., Seshadri, M., Goodrich, Z. W., Goodrich, M. M., Labbé, D. P., Gomez, E. C., Wang, J., et al. (2017) · Science · doi:10.1126/science.aah4199 · Cited by 1,089
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Adalsteinsson, V. A., Ha, G., Freeman, S. S., Choudhury, A. D., Stover, D. G., Parsons, H. A., Gydush, G., Reed, S. C., Rotem, D., Rhoades, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00965-y · Cited by 1,051
Mu, P., Zhang, Z., Benelli, M., Karthaus, W. R., Hoover, E., Chen, C.-C., Wongvipat, J., Ku, S.-Y., Gao, D., Cao, Z., et al. (2017) · Science · doi:10.1126/science.aah4307 · Cited by 1,050
The long tail of oncogenic drivers in prostate cancer
PCF/SU2C International Prostate Cancer Dream Team, Armenia, J., Wankowicz, S. A. M., Liu, D., Gao, J., Kundra, R., Reznik, E., Chatila, W. K., Chakravarty, D., Han, G. C., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0078-z · Cited by 867
Self-citationMateo, J., Porta, N., Bianchini, D., McGovern, U., Elliott, T., Jones, R., Syndikus, I., Ralph, C., Jain, S., Varughese, M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30684-9 · Cited by 634
Self-citationGenomic hallmarks of localized, non-indolent prostate cancer
Fraser, M., Sabelnykova, V. Y., Yamaguchi, T. N., Heisler, L. E., Livingstone, J., Huang, V., Shiah, Y.-J., Yousif, F., Lin, X., Masella, A. P., et al. (2017) · Nature · doi:10.1038/nature20788 · Cited by 600
Abida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., Danila, D., Rathkopf, D., Morris, M., Slovin, S., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00029 · Cited by 541
Annala, M., Vandekerkhove, G., Khalaf, D., Taavitsainen, S., Beja, K., Warner, E. W., Sunderland, K., Kollmannsberger, C., Eigl, B. J., Finch, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0937 · Cited by 515
Spatial genomic heterogeneity within localized, multifocal prostate cancer
Boutros, P. C., Fraser, M., Harding, N. J., de Borja, R., Trudel, D., Lalonde, E., Meng, A., Hennings-Yeomans, P. H., McPherson, A., Sabelnykova, V. Y., et al. (2015) · Nature Genetics · doi:10.1038/ng.3315 · Cited by 477
Clarke, N., Wiechno, P., Alekseev, B., Sala, N., Jones, R., Kocak, I., Chiuri, V. E., Jassem, J., Fléchon, A., Redfern, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30365-6 · Cited by 396
Self-citationWNT signalling in prostate cancer
Murillo-Garzón, V., & Kypta, R. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.144 · Cited by 361
Aparicio, A. M., Shen, L., Tapia, E. L. N., Lu, J.-F., Chen, H.-C., Zhang, J., Wu, G., Wang, X., Troncoso, P., Corn, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1259 · Cited by 295
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
CAMCAP Study Group, Wedge, D. C., The TCGA Consortium, Gundem, G., Mitchell, T., Woodcock, D. J., Martincorena, I., Ghori, M., Zamora, J., Butler, A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0086-z · Cited by 224
Self-citationHussain, M., Daignault-Newton, S., Twardowski, P. W., Albany, C., Stein, M. N., Kunju, L. P., Siddiqui, J., Wu, Y.-M., Robinson, D., Lonigro, R. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7310 · Cited by 206
Blattner, M., Liu, D., Robinson, B. D., Huang, D., Poliakov, A., Gao, D., Nataraj, S., Deonarine, L. D., Augello, M. A., Sailer, V., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.004 · Cited by 204
SPOP mutation leads to genomic instability in prostate cancer
Boysen, G., Barbieri, C. E., Prandi, D., Blattner, M., Chae, S.-S., Dahija, A., Nataraj, S., Huang, D., Marotz, C., Xu, L., et al. (2015) · eLife · doi:10.7554/elife.09207 · Cited by 193
Self-citationPatient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests
Torga, G., & Pienta, K. J. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4027 · Cited by 180
De Laere, B., Oeyen, S., Mayrhofer, M., Whitington, T., van Dam, P.-J., Van Oyen, P., Ghysel, C., Ampe, J., Ost, P., Demey, W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1943 · Cited by 174
Henzler, C., Li, Y., Yang, R., McBride, T., Ho, Y., Sprenger, C., Liu, G., Coleman, I., Lakely, B., Li, R., et al. (2016) · Nature Communications · doi:10.1038/ncomms13668 · Cited by 173
Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity
Løvf, M., Zhao, S., Axcrona, U., Johannessen, B., Bakken, A. C., Carm, K. T., Hoff, A. M., Myklebost, O., Meza-Zepeda, L. A., Lie, A. K., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.08.009 · Cited by 165
Chen, W. S., Aggarwal, R. R., Zhang, L., Zhao, S. G., THOMAS, G. V., Beer, T. M., Quigley, D. A., Foye, A., Playdle, D., Huang, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.03.020 · Cited by 139
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Lambros, M. B. K., Seed, G., Sumanasuriya, S., Gil, V., Crespo, M., Fontes, M. S., Chandler, R., Mehra, N., Fowler, G., Ebbs, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0862 · Cited by 109
Self-citationBarnell, E. K., Ronning, P., Campbell, K. M., Krysiak, K., Ainscough, B. J., Sheta, L. M., Pema, S. P., Schmidt, A. D., Richters, M. M., Cotto, K. C., et al. (2018) · Genetics in Medicine · doi:10.1038/s41436-018-0278-z · Cited by 107
Hussain, M., Carducci, M. A., Slovin, S. F., Cetnar, J. P., Qian, J. X., McKeegan, E. M., Refici-Buhr, M., Chyla, B., Shepherd, S. P., Giranda, V. L., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0099-0 · Cited by 98
Marshall, C. H., Fu, W., Wang, H., Baras, A. S., Lotan, T. L., & Antonarakis, E. S. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0086-1 · Cited by 90
Activation of β-Catenin Signaling in Androgen Receptor–Negative Prostate Cancer Cells
Wan, X., Liu, J., Lu, J.-F., Tzelepi, V., Yang, J., Starbuck, M. W., Diao, L., Wang, J., Efstathiou, E., Vazquez, E. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2521 · Cited by 79
Ong, M., Carreira, S., GOODALL, J. C., Mateo, J., Figueiredo, I., Rodrigues, D. N., Perkins, G., Seed, G., Yap, T. A., Attard, G., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.350 · Cited by 40
Self-citationManChon, U., Talevich, E., Katiyar, S., Rasheed, K., & Kannan, N. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003545 · Cited by 33
Seed, G., Yuan, W., Mateo, J., Carreira, S., Bertan, C. M., Lambros, M. B. K., Boysen, G., Ferraldeschi, R., Miranda, S., Figueiredo, I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0972 · Cited by 32
Self-citation
Cited by
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Sandhu, S., Moore, C. M., Chiong, E., Beltran, H., Bristow, R. G., & Williams, S. G. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00950-8 · Cited by 583
Self-citationGenomic and phenotypic heterogeneity in prostate cancer
Haffner, M. C., Zwart, W., Roudier, M. P., True, L. D., Nelson, W. G., Epstein, J. I., De Marzo, A. M., Nelson, P. S., & Yegnasubramanian, S. (2021) · Nature Reviews Urology · doi:10.1038/s41585-020-00400-w · Cited by 502
Pan-cancer whole-genome comparison of primary and metastatic solid tumours
Martínez-Jiménez, F., Movasati, A., Brunner, S. R., Nguyen, L., Priestley, P., Cuppen, E., & Van Hoeck, A. (2023) · Nature · doi:10.1038/s41586-023-06054-z · Cited by 285
Yap, T. A., Tan, D. S. P., Terbuch, A., Caldwell, R., Guo, C., Goh, B. C., Heong, V., Haris, N. R. M., Bashir, S., Drew, Y., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0868 · Cited by 262
Self-citation
Metadata
- Authors
- Mateo, J., Seed, G., Bertan, C., Rescigno, P., Dolling, D., Figueiredo, I., Miranda, S., Nava Rodrigues, D., Gurel, B., Clarke, M., Atkin, M., Chandler, R., Messina, C., Sumanasuriya, S., Bianchini, D., Barrero, M., Petermolo, A., Zafeiriou, Z., Fontes, M., Perez-Lopez, R., Tunariu, N., Fulton, B., Jones, R., McGovern, U., Ralph, C., Varughese, M., Parikh, O., Jain, S., Elliott, T., Sandhu, S., Porta, N., Hall, E., Yuan, W., Carreira, S., & de Bono, J. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-02-24
- Volume
- 130
- Issue
- 4
- Pages
- 1743-1751
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2997243361
- Cited by
- 313
- References
- 41
- FWCI
- 22.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.